TNF and uveitis: Thirty-seven patients (21 males; 16 females) with a history of uveitis (62 eyes involved) were switched from originator anti-TNF-α biological agents to biosimilars as follows: Imraldi® (n = 20 patients, 33 eyes involved); Flixabi® (n = 10 patients, 16 eyes involved); Inflectra® (n = 5 patients, 9 eyes involved); Benepali® (n = 2 patients, 4 eyes involved).